This browser doesn't support Spotify Web Player. Switch browsers or download Spotify for your desktop.

PeerVoice Oncology & Haematology Audio

By PeerVoice

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

  1. 1.
    Novel Therapies for Patients With DLBCL: What Does the Future Hold?10/22/2020
    1:04:21
  2. 2.
    New Targets in Heart Failure: Congress Updates on SGLT2 Inhibitors10/21/2020
    12:32
  3. 3.
    A Patient-Centred Approach to Managing Prostate Cancer09/30/2020
    17:28
  4. 4.
    Deciphering the Role of MET Alterations in Advanced NSCLC: Unmet Needs09/28/2020
    15:42
  5. 5.
    Are All Biologics the Same? Optimal Treatment Strategies for Patients With Inflammatory Bowel Disease09/21/2020
    21:28
  6. 6.
    Hidden in Plain Sight: Uncovering Truncal Acne09/09/2020
    13:03
  7. 7.
    Extending Your Interdisciplinary Understanding of IL-6R Inhibitors in Rheumatoid Arthritis09/07/2020
    1:15:18
  8. 8.
    New Targets, New Hope in SMA: A 2020 Congress Coverage09/04/2020
    27:48
  1. 9.
    "Optimising the Use of JAK Inhibitors in RA: Translating the Latest Evidence Into Today’s Clinical Practice"08/17/2020
    23:26
  2. 10.
    Talking Meningococcal B Vaccines: Who Needs Protecting Now?08/12/2020
    20:01
  3. 11.
    Defining a Patient-Centred Approach to Non-Metastatic Castration-Resistant Prostate Cancer07/01/2020
    1:19:30
  4. 12.
    Treatment Update in CML: What’s New, and What Does it Mean for Patients?06/26/2020
    20:48
  5. 13.
    "Case Studies in Locally Advanced and Metastatic CSCC: Integrating Immunotherapy Into Current Treatment Paradigms"06/22/2020
    20:12
  6. 14.
    Hiding in Plain Sight: Identifying Patients at Risk for NASH06/19/2020
    24:34
  7. 15.
    Practical Lessons From Real-World Evidence on CDK 4/6 Inhibitors in Metastatic Breast Cancer05/18/2020
    22:01
  8. 16.
    Changing Strategies for Changing Times: Optimising Use of Targeted Alpha Therapies for Advanced Prostate Cancer05/13/2020
    23:32
  9. 17.
    Raising the Caliber of Non-Metastatic CRPC Care: Introducing Quality of Life Into the Equation05/08/2020
    37:42
  10. 18.
    Evolving the Treatment Paradigm in HER2-Positive Breast Cancer: Are New Options on the Horizon?02/21/2020
    15:22
  11. 19.
    Sequencing Therapy in mRCC: How Does an Evolving Treatment Pathway Change Decisions?01/13/2020
    16:06
  12. 20.
    Evolution of Paroxysmal Nocturnal Haemoglobinuria: Complementing Current Approaches to Management12/27/2019
    30:25
  13. 21.
    Immuno-oncology for mRCC: Considerations for a Combination Approach in the First-Line Setting12/04/2019
    18:34
  14. 22.
    Recognising and Addressing Burden of Disease in Adolescents With Moderate-to-Severe AD12/02/2019
    19:33
  15. 23.
    Heading Toward a More Successful Approach to Migraine Management11/27/2019
    13:40
  16. 24.
    Choose Your Own HS Adventure: Going Beyond Current Guidelines11/15/2019
    57:29
  17. 25.
    Warming Up to Novel Approaches for Primary Cold Agglutinin Disease: Strategies for Correct Diagnosis and Optimal Treatment11/04/2019
    16:08
  18. 26.
    PARP Inhibitors for Ovarian Cancer: Making the Right Choices at the Right Times10/30/2019
    9:52
  19. 27.
    Paving the Way to Better Outcomes in EGFR-Mutant NSCLC: Time to Take a Step Further?10/16/2019
    1:07:42
  20. 28.
    Maximising the Long-Term Treatment Plan for Unresectable Hepatocellular Carcinoma: A Sequential Approach to Improving Patient Outcomes07/08/2019
    20:47
  21. 29.
    The Power of Personalised Medicine: CAR-T Immunotherapy for Treatment of Aggressive Large B-Cell Lymphoma07/05/2019
    21:54
  22. 30.
    Optimising the Treatment of mRCC From the Start: Evaluating the Impact of Evolving First-Line Strategies06/10/2019
    16:40
  23. 31.
    Beyond Positive and Negative HER2 Status: Defining HER2 Levels in Breast Cancer05/27/2019
    19:30
  24. 32.
    Aiming Higher in Advanced Cutaneous Squamous Cell Carcinoma: Experts Evaluate the Evidence for Immunotherapy05/17/2019
    28:35
  25. 33.
    Emerging ‘Tumour-Agnostic’ Oncology Treatment: The Role of the Pathologist in Identifying Neurotrophic Tyrosine Kinase Gene Fusions05/03/2019
    25:58
  26. 34.
    Merging Clinical Trial Results and Reality: The Real-World Implications of Androgen Receptor Antagonists for Non–Metastatic Castration-Resistant Prostate Cancer04/29/2019
    29:06
  27. 35.
    Optimising Outcomes for Young Women With Breast Cancer: The Role of Adjuvant Ovarian Suppression03/15/2019
    21:05
  28. 36.
    Managing Patients With HER2-Low Breast Cancer02/19/2019
    14:29
  29. 37.
    Is There a Cardio-Oncologist in the House? Managing Risk for VTE and Stroke Due to AF in Patients With Cancer02/07/2019
    19:41
  30. 38.
    Biomarkers in Lung Cancer: Targeting the Right Patient With the Right Therapy11/26/2018
    1:14:45
  31. 39.
    Paroxysmal Nocturnal Haemoglobinuria: Complementing Current Knowledge To Improve Outcomes09/28/2018
    28:08
  32. 40.
    Best Practices for Use of Proteasome Inhibitors in the Treatment of Relapsed/Refractory Multiple Myeloma09/20/2018
    19:11
  33. 41.
    Best Practices in Managing CML08/17/2018
    17:59
  34. 42.
    Clinical Updates: New Pathways and Strategies in Small-Cell Lung Cancer07/04/2018
    19:09
  35. 43.
    Improving Treatment Monitoring and Therapy Selection in Metastatic Castration-Resistant Prostate Cancer06/06/2018
    16:15
  36. 44.
    Locally Advanced BCC: Selecting the Right Option to Optimise Outcomes in Your Patients05/11/2018
    18:38
  37. 45.
    Improving the Long-Term Treatment Plan for Patients With Metastatic Pancreatic Cancer: Insights From San Francisco05/09/2018
    8:25
  38. 46.
    The Treatment Plan for Patients With Nonmetastatic Prostate Cancer in Canada: Optimizing the Journey From The Beginning05/03/2018
    26:10
  39. 47.
    Emerging Biomarkers in Small-Cell Lung Cancer: A New Era04/30/2018
    16:44
  40. 48.
    Improving Outcomes in Later Lines of Therapy for Metastatic Colorectal Cancer04/11/2018
    18:48
  41. 49.
    New Strategies, New Targets: The Evolving Landscape in Driver-Mutation–Positive Advanced NSCLC04/09/2018
    11:04
  42. 50.
    Improving Outcomes for VTE in Cancer: The Role of Oral Anticoagulants03/19/2018
    20:08

Listen to PeerVoice Oncology & Haematology Audio now.

Listen to PeerVoice Oncology & Haematology Audio in full in the Spotify app